



## THE 14<sup>th</sup> SUGIYAMA LABORATORY (RIKEN) OPEN SYMPOSIUM

“From Drug screening, selection, translation to clinical development”

Date : 12:40 - 17:50, October 11<sup>th</sup>, 2019

Venue : RIKEN Yokohama Main Office Building Hall

- 12:40-12:45 Opening remarks  
Yuichi Sugiyama (Sugiyama Laboratory, RIKEN)
- 12:45-13:25 **【Key note Lecture】**  
ADME Characterization and Application of Translational Modeling in Drug Discovery; impact, opportunities and challenges  
Marjoleen Nijsen (AbbVie Inc.)
- 13:25-17:50 **[Round table discussion on  
“From Drug screening, selection, translation to clinical development”]**
- 13:25-13:50 Prediction of major clearance pathway using in silico approach.  
Kimio Tohyama (Takeda Pharmaceutical Company Limited)
- 13:50-14:15 Application of in silico ADME prediction in drug discovery stage.  
Daisuke Sugiyama (DAIICHI SANKYO COMPANY, LIMITED)
- 14:15-14:40 Prediction of human hepatic clearance for OATP1B substrate drugs by in vitro-in vivo extrapolation approaches  
Yoshitane Nozaki (Eisai Co., Ltd.)
- 14:40-15:05 Coffee break
- 15:05-15:30 Extended Clearance Classification System (ECCS) approach in drug discovery - OAT2 contribution to hepatic clearance for ECCS1A compounds  
Emi Kimoto (Pfizer Inc.)
- 15:30-15:55 Pharmacokinetics and Pharmacogenomics Characterization of Compound X - From Discovery to Clinic.  
Ryota Kikuchi (AbbVie Inc.)
- 15:55-16:20 Prediction and mechanistic evaluation of clinical DDI with transporter endogenous biomarkers.  
Kenta Yoshida (Genentech inc.)
- 16:20-16:45 The Strategic implementation of MIDD in the early clinical development.  
(15+10)  
Akihiro Yamada (Astellas Pharma Inc.)
- 16:45-17:00 Break
- 17:00-17:50 **General** discussion



Yuichi Sugiyama (Sugiyama Laboratory, RIKEN)

18:00-19:45 Banquet (Cafeteria at Yokohama RIKEN)

[This Symposium is a part of the RIKEN Symposium Series.]